Thomas M. Stackhouse, Ph.D.

Dr. Stackhouse is the current Assistant Director for the Technology Transfer Center at the National Cancer Institute-Frederick.  In this position, Dr. Stackhouse oversees NCI-Frederick’s partnering activities through NCI Collaboration Agreements and CRADAs and manages their intellectual property portfolio.  The NCI –Frederick campus is composed of staff from both NCI and a system of contracts and is the only designated Federally Funded Research and Development Center (FFRDC) within DHHS.  Dr. Stackhouse plays a lead role in establishing the IP parameters and guidelines for several key NCI initiatives which have been handled through the NCI-Frederick campus including:  the Full-Length cDNA Initiative, The Chemical Genomics Initiative, the Proteomics Initiative and the NCI’s Alliance for Nanotechnology in Cancer.   Prior to joining the NCI-Technology Transfer staff in 1996, Dr. Stackhouse received his B.S. in Microbiology from the Pennsylvania State University and then joined a lab at PSU studying the mechanism of protein folding.  Dr. Stackhouse then obtained his Ph.D. in Biochemistry from the University of California, Davis where studied the regulation of gene expression.  After obtaining his Ph.D., Dr. Stackhouse was a Developmental Scientist for a major pharmaceutical company and was later part of an NCI-led research team of scientists who discovered the VHL tumor suppressor gene.  Dr. Stackhouse received the National Institutes of Health Award of Merit for his outstanding management of the NCI-Frederick Technology Transfer office.